All In Biotech

Drug Trial Radar · NCT02105012

Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma

Randomized, Double-Blind, Chronic Dosing (4 Weeks), Four-Period, Five-Treatment, Incomplete Block, Cross-Over, Multi-Center Study to Assess the Efficacy and Safety of Four Doses of Budesonide Inhalation Aerosol (BD MDI, PT008) Relative to Placebo MDI in Adult Subjects With Mild to Moderate Persistent Asthma

Last checked: Nov 19, 2026Latest source record: Jun 6, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 147 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

147

Actual

Start

Apr 1, 2014

Primary completion

Sep 1, 2015

Study completion Sep 4, 2015

Sponsor

Lead sponsor
Pearl Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Apr 7, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study to assess the efficacy and safety of four doses of budesonide inhalation aerosol (BD MDI, PT008) relative to placebo MDI in adult subjects with mild to moderate persistent asthma.

Conditions

  • Asthma

Interventions

  • BD MDI 320 µgDrug

    Budesonide Inhalation Aerosol administered as 2 inhalations BID

  • BD MDI 160 µgDrug

    Budesonide Inhalation Aerosol administered as 2 inhalations BID

  • BD MDI 80 µgDrug

    Budesonide Inhalation Aerosol administered as 2 inhalations BID

  • BD MDI 40 µgDrug

    Budesonide Inhalation Aerosol administered as 2 inhalations BID

  • Placebo MDIDrug

    Placebo MDI administered as 2 inhalations BID

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Morning Pre-dose Trough Forced Expiratory Volume in 1 Second (FEV1) at the End of the Treatment PeriodTime frame: Baseline to End of Treatment Period (Day 29 or Day 15 if Day 29 is missing)

Locations

41 sites in 1 country. Site status is shown where the registry gives one.

  • Pearl Therapeutics Study Site

    Athens, Alabama

  • Pearl Therapeutics Study Site

    Birmingham, Alabama

  • Pearl Therapeutics Study Site

    Foley, Alabama

  • Pearl Therapeutics Study Site

    Los Angeles, California

  • Pearl Therapeutics

    Los Angeles, California

  • Pearl Therapeutics Study Site

    Rolling Hills Estates, California

  • Pearl Therapeutics Study Site

    San Diego, California

  • Pearl Therapeutics Study Site

    Stockton, California

  • Pearl Therapeutics Study Site

    Clearwater, Florida

  • Pearl Therapeutics Study Site

    Clermont, Florida

  • Pearl Therapeutics Study Site

    Miami, Florida

  • Pearl Therapeutics Study Site

    Orlando, Florida

  • Pearl Therapeutics Study Site

    Ormond Beach, Florida

  • Pearl Therapeutics Study Site

    Saint Cloud, Florida

  • Pearl Therapeutics Study Site

    Sebring, Florida

  • Pearl Therapeutics Study Site

    Tampa, Florida

  • Pearl Therapeutics Study Site

    Blue Island, Illinois

  • Pearl Therapeutics Study Site

    North Dartmouth, Massachusetts

  • Pearl Therapeutics Study Site

    Hazelwood, Missouri

  • Pearl Therapeutics Study Site

    Skillman, New Jersey

  • Pearl Therapeutics Study Site

    Charlotte, North Carolina

  • Pearl Therapeutics Study Site

    Winston-Salem, North Carolina

  • Pearl Therapeutics Study Site

    Cincinnati, Ohio

  • Pearl Therapeutics Study Site

    Columbus, Ohio

  • Pearl Therapeutics Study Site

    Dayton, Ohio

  • Pearl Therapeutics Study Site

    Middleburg Heights, Ohio

  • Pearl Therapeutics Study Site

    Oregon, Ohio

  • Pearl Therapeutics Study Site

    Sylvania, Ohio

  • Pearl Therapeutics Study Site

    Toledo, Ohio

  • Pearl Therapeutics Study Site

    Oklahoma City, Oklahoma

  • Pearl Therapeutics Study Site

    Lake Oswego, Oregon

  • Pearl Therapeutics Study Site

    Medford, Oregon

  • Pearl Therapeutics Study Site

    Greenville, South Carolina

  • Pearl Therapeutics Study Site

    Spartanburg, South Carolina

  • Pearl Therapeutics Study Site

    Rapid City, South Dakota

  • Pearl Therapeutics Study Site

    Tullahoma, Tennessee

  • Pearl Therapeutics Study Site

    El Paso, Texas

  • Pearl Therapeutics Study Site

    Houston, Texas

  • Pearl Therapeutics Study Site

    Plano, Texas

  • Pearl Therapeutics Study Site

    San Antonio, Texas

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.